Protocol Ledger

NCT06869551 · Phase III · RECRUITING

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

Interventional Phase III clinical trial protocol NCT06869551 sponsored by Bristol Myers Squibb in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-13 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06869551
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06869551
Protocol FieldVerified Registry Value
NCT IdentifierNCT06869551
Consolidated Lead SponsorBristol Myers Squibb
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2025-03-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06869551
Hospital Research SiteLocationSite Profile
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Fakultni Nemocnice OlomoucOlomouc, CzechiaOpen Hospital Dossier ->
Fakultni nemocnice v MotolePrague, CzechiaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI